



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 6 : C12N 15/85, 15/86, 15/62, 9/12, C07K 14/21, 19/00, A61K 48/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 98/13508 (43) International Publication Date: 2 April 1998 (02.04.98)</p>
<p>(21) International Application Number: PCT/US97/17143 (22) International Filing Date: 24 September 1997 (24.09.97) (30) Priority Data: 60/026,959 24 September 1996 (24.09.96) US (71) Applicant (for all designated States except US): DANA-FARBER CANCER INSTITUTE [US/US]; 44 Binney Street, Boston, MA 02115 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): FINE, Howard, A. [US/US]; 352 Commonwealth Avenue, Unit 4, Boston, MA 02115 (US). KAELIN, William, Jr. [US/US]; 12 Commonwealth Avenue, Boston, MA 02116 (US). (74) Agents: EISENSTEIN, Ronald, I. et al.; Dike, Bronstein, Roberts & Cushman, LLP, 130 Water Street, Boston, MA 02109 (US).</p>		<p>(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SI). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>

(54) Title: METHOD OF TARGETING MALIGNANT CELLS USING AN E2F RESPONSIVE PROMOTER

(57) Abstract

A method of selectively expressing a gene in a malignant as opposed to a non-malignant cell is taught. This permits one to selectively express proteins that would be deleterious to normal cells with minimal harm. The method involves the use of a nucleic acid cassette having an E2F responsive promoter operably linked to a gene of interest, which encodes either a positive or negative potentiator such as antibodies, dominant negative mutants, suicide genes, antisense RNA, ribozymes and cytotoxic agents.